Connect with us
Wegovy stands as Novo Nordisk's big bet. This medicine was what placed the Danish multinational company as the most valuable company in Europe last September, surpassing...
Eli Lilly's U.S. revenues grew by 39% to 6,188.1 million euros, with international revenues up 10% to 2.7 billion euros. R&D costs rose by 29.5%, while...
BlackRock increased its stake in Grifols to 4.2% amid the Spanish company's legal dispute with Gotham City Research. The 4.1% rise in Grifols' stock boosted the...
Almirall collaborates with Microsoft to enhance dermatological innovation through AI techniques, improving data analysis, developing synthesizable molecules, and optimizing data management processes in drug discovery. The...
In 2024, Novo Nordisk expects its sales to increase between 18% and 26% at constant exchange rates, while it anticipates operating profit growth at constant exchange...
The approval of the treatment is based on two pivotal phase III clinical trials: M15-741 and M-15-736. Primary endpoint results from the first trial showed that...
The Spanish health AI sector will go from moving €130 million in 2022 to generating €2.5 billion in 2030. Companies such as Almirall, Grifols or Faes...
There are also signs to anticipate the entry into a consolidation phase of the digital health business. The merger and acquisition (M&A) of companies in this...
In December 2023, the company reached an agreement to acquire the entire share capital of the Chinese start-up Gracell Biotechnologies for a price that could reach...
The path laid out by general pharmaceutical legislation, according to the Asebio study's conclusions, makes it less likely to achieve objectives related to, for example, rare...
 |
|
 |  |
 |
|